ARCH Venture Partners closes latest fund at just shy of $3 billion
ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 Billion ARCH Venture Fund XI.
According to the news release issued by the firm, ARCH investments made from Fund XII will reflect the firm’s focus on companies formed around breakthrough technologies. This means investing in early stage biotechnology companies with potential to solve some of the biggest health challenges in areas including infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, and ways to reimagine diagnostics and therapies.
“Our approach has always been to pair great science with remarkable, proven teams to build disruptive companies. We believe in this model now more than ever. The science happening today is simply stunning and provides a broad base of innovation and discovery to bring forward,” said ARCH Managing Director Kristina Burow.
